Addex Announces Participation in the H.C. Wainwright 25th
Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Source: globenewswire.com
📰 Tim Dyer News
Page 3 - Tim Dyer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tim Dyer. Real-time updates on events, politics, business and more.
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 -Today at 01:01 am
Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company...
United States Mike Sinclair Tim Dyer Janssen Pharmaceuticals Inc Janssen Pharmaceutical Companies Of Johnson Swiss Exchange
Source: marketscreener.com
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout
Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex...
United States Mike Sinclair Tim Dyer Swiss Exchange Janssen Pharmaceutical Companies Of Johnson Janssen Pharmaceuticals Inc
Source: globenewswire.com
Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-strok...
Source: businessinsider.com
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update - Addex Therapeutics (NASDAQ:ADXN)
ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendationIndivior GABAB PAM collaboration extended to June 2024 with CHF 2.7 million of
United States Addex Therapeutics Tim Dyer Mikhail Kalinichev Janssen Pharmaceuticals Inc Swiss Exchange
Source: benzinga.com
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
Geneva, Switzerland, August 3, 2023 – Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will...
Source: marketscreener.com
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 24, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that administration of a metabotropic glutamate 2 (mGlu2) positive allosteric modulator significantly
United States Tim Dyer Mike Sinclair Scripps Research Institute Janssen Pharmaceuticals Inc Swiss Exchange
Source: yahoo.com
Kayak buying 101
Are you interested in taking up kayaking at the cottage this summer? Before you buy, learn how to choose for the best fit
Source: cottagelife.com
Addex Increases Issued Share Capital to Create Treasury Shares - Addex Therapeutics (NASDAQ:ADXN)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 15, 2023 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and
Source: benzinga.com
Addex Receives Nasdaq Notification Regarding Minimum Bid
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
United States Mike Sinclair Tim Dyer Swiss Exchange Janssen Pharmaceuticals Inc Company American Depositary Shares Adss
Source: globenewswire.com